
-
Scorching 1,500m return for Olympic great Ledecky in Florida
-
Israel's Netanyahu warns wildfires could reach Jerusalem
-
Istanbul lockdown aims to prevent May Day marches
-
Australian guard Daniels of Hawks named NBA's most improved
-
Mexico City to host F1 races until 2028
-
Morales vows no surrender in bid to reclaim Bolivian presidency
-
Ukraine, US sign minerals deal, tying Trump to Kyiv
-
Phenomenons like Yamal born every 50 years: Inter's Inzaghi
-
Ukraine, US say minerals deal ready as Kyiv hails sharing
-
Global stocks mostly rise following mixed economic data
-
O'Sullivan says he must play better to win eighth snooker world title after seeing off Si Jiahui
-
Sabalenka eases past Kostyuk into Madrid Open semis
-
Netflix's 'The Eternaut' echoes fight against tyranny: actor Ricardo Darin
-
US economy unexpectedly shrinks, Trump blames Biden
-
Barca fight back against Inter in sensational semi-final draw
-
Meta quarterly profit climbs despite big cloud spending
-
US Supreme Court weighs public funding of religious charter school
-
Climate change made fire conditions twice as likely in South Korea blazes: study
-
Amorim says not even Europa League glory can save Man Utd's season
-
Syria reports Israeli strikes as clashes with Druze spread
-
Ukraine, US say minerals deal ready as suspense lingers
-
Everything is fine: Trump's cabinet shrugs off shrinking economy
-
Chelsea boss Maresca adamant money no guarantee of success
-
Wood warns England cricketers against 'dumb' public comments
-
US economy shrinks, Trump blames Biden
-
Caterpillar so far not hiking prices to offset tariff hit
-
Japan's Kawasaki down Ronaldo's Al Nassr to reach Asian Champions League final
-
Trump praises Musk as chief disruptor eyes exit
-
Chahal hat-trick helps Punjab eliminate Chennai from IPL playoff race
-
Pope Francis saw clergy's lack of humility as a 'cancer': author
-
Weinstein accuser recounts alleged rape at assault retrial in NY
-
Piastri heads into Miami GP as the man to beat
-
US economy unexpectedly shrinks in first quarter, Trump blames Biden
-
Maxwell likely to miss rest of IPL with 'fractured finger'
-
Syria reports Israeli strikes after warning over Druze as sectarian clashes spread
-
Despite war's end, Afghanistan remains deep in crisis: UN relief chief
-
NFL fines Falcons and assistant coach over Sanders prank call
-
British teen Brennan takes stage 1 of Tour de Romandie
-
Swedish reporter gets suspended term over Erdogan insult
-
Renewable energy in the dock in Spain after blackout
-
South Africa sets up inquiry into slow apartheid justice
-
Stocks retreat as US GDP slumps rattles confidence
-
Migrants' dreams buried under rubble after deadly strike on Yemen centre
-
Trump blames Biden's record after US economy shrinks
-
UK scientists fear insect loss as car bug splats fall
-
Mexico avoids recession despite tariff uncertainty
-
Rwandan awarded for saving grey crowned cranes
-
Spurs have 'unbelievable opportunity' for European glory: Postecoglou
-
Microsoft president urges fast 'resolution' of transatlantic trade tensions
-
Poppies flourish at Tower of London for WWII anniversary

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Company achieves another milestone relating to its clinical trial strategy
HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it has received Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.
One clinical trial site has been activated with patient enrollment expected to total six to eight participants and the trials are expected to begin this week.
"The purpose of IRB review is to assure that appropriate steps are taken to protect the rights and welfare of individuals participating as subjects in clinical research," said Kraig Higginson, Chief Executive Officer of Aspire. "With this centralized IRB approval, we have achieved another significant clinical milestone. We remain focused on completing our preparations for the clinical trial of our oral transmucosal fast-acting high-dose aspirin formulation and look forward to its commencement."
Phase 1 Study Design
The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when administered orally in healthy adult volunteers. The Phase 1 clinical trial, which is being conducted in the United States, will compare the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers administered a sublingual dose of 162.5 mg aspirin powder with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post dose.) More information can be found at https://clinicaltrials.gov/
This Phase 1 trial is expected to provide information required to select the optimal drug product formulation and inform the design of a second clinical trial, if needed, to support FDA approval. Following completion of this trial, Aspire plans to submit a section 505(b)(2) NDA seeking fast-track approval to market the product for treatment of suspected acute myocardial infarction. An oral transmucosal acetylsalicylic acid (OTASA) product associated with rapid absorption and antiplatelet effects could provide important benefits for patients experiencing acute myocardial infarction where the benefits of aspirin in reducing the risk of vascular mortality are widely recognized and where every minute counts. In a large, multicenter study of aspirin, streptokinase, and the combination of aspirin and streptokinase in 17,187 patients with suspected acute MI, aspirin treatment produced a 23 percent reduction in the risk of vascular mortality. Aspirin was also shown to have an additional benefit in patients given a thrombolytic agent. (Source: https://pubmed.ncbi.nlm.nih.gov/2903874/ )
Greater bioavailability of ASA, through the oral mucosa (avoiding first pass metabolism) could also potentially improve pharmacodynamic effects of aspirin for patients on repeated-dose aspirin regimens while limiting the potential for direct irritation to the gastric mucosa that could be associated with gastric bleeding.
About the Aspire Targeted Oral Delivery Platform
Aspire's technology delivers a soluble, fast acting granular or powder form drug formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technologies new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream. The benefits of "rapid absorption" are to provide nearly instant treatment impact and high dose absorption. The Company's patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract, and potentially provide an improved treatment outcome.
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
D.Moore--AMWN